MedPath

A randomized controlled study of Shenfuhuang Compound in the treatment of sepsis

Phase 1
Conditions
sepsis
Registration Number
ChiCTR2400088940
Lead Sponsor
Beijing Hospital of Traditional Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

(1) consistent with the diagnosis of sepsis;<br>(2) age =18 years old;<br>(3) Voluntarily participated in this study and signed informed consent.

Exclusion Criteria

(1) pregnant or preparing for pregnancy;<br>(2) patients with severe mental disorders;<br>(3) the expected survival time of patients is less than 28 days due to underlying diseases, such as poor control of malignant tumors, cardiac arrest within the past 30 days, etc.;<br>(4) survival status of plants;<br>(5) confirmed or highly suspected acute infectious diseases, such as active viral hepatitis, active tuberculosis, etc.;<br>(6) allergy to the active ingredients of the test drug or its excipients;<br>(7) participated in clinical intervention trials within the past 3 months.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
28-day mortality;
Secondary Outcome Measures
NameTimeMethod
SOFA score;Length of ICU stay;DIC score;
© Copyright 2025. All Rights Reserved by MedPath